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ABSTRACT
Introduction: Diabetes therapy should balance
glycemic control with risk of adverse events.
This sub-analysis of the A1chieve study
evaluated clinical safety and effectiveness of
insulin detemir in different age-groups
(B40 years, [40–65 years, and [65 years) of
insulin-experienced and insulin-naı¨ve people
with type 2 diabetes.
Methods: A1chieve was an international, open-
label, non-interventional, 24-week study in
66,726 people with type 2 diabetes starting/
switching to therapy with biphasic insulin
aspart 30, insulin detemir or insulin aspart
(alone/in combination) in routine clinical
practice. This sub-analysis evaluated clinical
safety and effectiveness in patients starting/
switching to insulin detemir (±oral glucose-
lowering drugs).
Results: In total, 15,241 patients were included
in the sub-analysis. In all age-groups, the
proportion of participants experiencing any,
major or nocturnal hypoglycemia was
significantly (all p\0.05) reduced relative to
baseline, except in insulin-naı¨ve patients for
any and nocturnal hypoglycemia, where there
was a significant increase or no significant
change in patients aged [65 years and
The A1chieve trial was registered with ClinicalTrials.gov
(NCT00869908).
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[40–65 years, respectively, and no significant
change in major hypoglycemia in insulin-naı¨ve
patients aged B40 years. Seven serious adverse
drug reactions were reported. Body weight was
significantly reduced in patients aged B40 years
and [40–65 years and significantly increased in
insulin-naı¨ve patients aged [65 years at
24 weeks. At 24 weeks, glycated hemoglobin
was reduced by 2.3%, 2.0%, and 1.8%, in the
B40 years, [40–65 years, and [65 years age-
groups, respectively (all p\0.001). Fasting and
post-prandial plasma glucose were significantly
reduced and health-related quality of life
(HRQoL) significantly improved across all
patient cohorts (all p\0.001).
Conclusion: After 24-week treatment with
insulin detemir, all age-groups of insulin-
experienced and insulin-naı¨ve patients had
significantly improved glycemic control and
HRQoL. The proportion of patients experiencing
hypoglycemia was reduced in all age-groups but
unchanged in insulin-naı¨ve patients aged[40–65
years and increased in insulin-naı¨ve patients aged
[65 years. The safety and effectiveness of insulin
detemir may benefit all age-groups.
Keywords: Hypoglycemia; Insulin detemir;
Type 2 diabetes
INTRODUCTION
The prevalence of diabetes is increasing
worldwide [1]. Good glycemic control is an
important goal of diabetes treatment to prevent
and/or delay long-term microvascular
complications [2, 3]. Current guidelines from
the International Diabetes Federation (IDF) and
joint American Diabetes Association (ADA)/
European Association for the Study of Diabetes
(EASD) recommend the glycated hemoglobin
(HbA1c) target of \7.0%, with some
individualization according to age [4–6]. For
example, the IDF recommends the HbA1c target
of 7.0–7.5% for people with type 2 diabetes aged
70 years or older [4], and California Healthcare
Foundation/American Geriatrics Society Panel
guidelines recommend the target of \7.0% for
people with diabetes aged 65 years or older [7].
The ADA/EASD position statement [5] and
IDF guidelines [4] for type 2 diabetes recommend
initiating insulin therapy with basal (long-
acting) insulin if glycemic target is not achieved
with metformin alone or in combination with
other oral medications. Insulin detemir
(Levemir, Novo Nordisk A/S, Bagsvaerd,
Denmark) is a long-acting insulin analog with a
duration of action of up to 24 h [8–10].
Randomized, parallel studies have shown that
insulin detemir, given as add-on therapy to oral
glucose-lowering drugs (OGLDs) in people with
uncontrolled type 2 diabetes, is associated with
reduced risk of hypoglycemia compared with
neutral protamine Hagedorn (NPH) [11, 12].
Furthermore, large observational studies in
people with type 2 diabetes have shown that
insulin detemir results in significantly reduced
HbA1c, fasting plasma glucose (FPG) and within-
patient FPG variability [13, 14], with low rates of
adverse events and hypoglycemia, and no weight
gain [13, 14].
A1chieve was an international non-
interventional study evaluating the clinical
safety and effectiveness of insulin analogs in
people with type 2 diabetes in everyday clinical
practice [15, 16]. The study demonstrated the
safety and effectiveness of these insulin analog
therapies [15], and significant improvements in
health-related quality of life (HRQoL) [16]. This
sub-analysis of data from A1chieve evaluated
the clinical safety and effectiveness of insulin
detemir in three age-groups. Additionally, the
data were analyzed by pre-study insulin
experience.
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MATERIALS AND METHODS
A1chieve was an international, multicenter,
prospective, open-label, non-interventional,
24-week study in people with type 2 diabetes
who had been receiving anti-diabetes
medication before starting, or switching to,
insulin therapy with biphasic insulin aspart 30
(NovoMix 30, Novo Nordisk A/S, Bagsvaerd,
Denmark), insulin detemir or insulin aspart
(NovoRapid, Novo Nordisk A/S, Bagsvaerd,
Denmark) (alone or in combination) in routine
clinical practice [15]. The study included
patients attending diabetes care clinics where
insulin therapy was initiated or modified at the
discretion of the treating physician, based on
their clinical judgment. The patients were
enrolled between January 2009 and June 2010
in 28 countries, which were grouped into seven
geographical regions: China; South Asia
(Bangladesh, India, Pakistan); East Asia
(Indonesia, Korea, Malaysia, Philippines,
Singapore, Taiwan); North Africa (Algeria,
Morocco, Tunisia, Libya); Middle East/Gulf
(Egypt, Iran, Jordan, Turkey, Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia, United Arab
Emirates, Yemen); Latin America (Argentina,
Mexico); and Russia [15]. The study was
conducted in accordance with the Guidelines
for Good Pharmacoepidemiology Practice [17]
and Declaration of Helsinki of 1964, as revised in
2008 [18]. All local requirements for Health
Authorities or Ethics Committee approvals, if
applicable, were acquired. All participants
signed informed consent forms and could
withdraw from the study at any time.
This sub-analysis included patients starting or
switching to treatment with insulin detemir alone
or in combination with OGLDs. To reflect routine
clinical practice as much as possible, inclusion and
exclusion criteria were minimal. Further details on
inclusion and exclusion criteria, and study design
were previously published [15]. Insulin detemir
was used according to the label approved by the
regulatory authority.
Assessments and Outcome Measures
Assessment sessions were defined as baseline,
interim [approximately 12 weeks from baseline
(results not reported here)] and study end
(approximately 24 weeks from baseline). The
primary objective was to assess the safety profile
of insulin detemir by evaluating the incidence
of serious adverse drug reactions (SADRs),
including major hypoglycemia events. An
additional safety assessment was change in the
number of hypoglycemia events between
baseline and 24 weeks, which was based on
patient recall of events within the last 4 weeks
prior to the study visit.
A hypoglycemia event was defined as an
event with symptoms of hypoglycemia that
resolved with oral carbohydrate intake,
glucagon or intravenous glucose, or any
symptomatic or asymptomatic event where
plasma glucose was \3.1 mmol/l or 56 mg/dl.
Nocturnal hypoglycemia events were defined as
individualized symptomatic events consistent
with hypoglycemia, occurring during sleep,
after the evening insulin injection and before
getting up in the morning; and if relevant,
before morning determination of FPG and the
morning insulin injection. Major hypoglycemia
events were defined as events with severe
central nervous system symptoms consistent
with hypoglycemia in which the patient was
unable to self-treat and had one of the following
characteristics: plasma glucose \3.1 mmol/l or
56 mg/dl, or reversal of symptoms after either
food intake, glucagon or intravenous glucose
administration.
The secondary objective was to investigate the
clinical effectiveness of insulin detemir.
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Effectiveness measurements comprised change in
HbA1c, FPG levels before breakfast, post-prandial
plasma glucose (PPG) levels after breakfast, body
weight, and HRQoL between baseline and
24 weeks. To assess the impact of insulin detemir
on HRQoL, this was assessed at baseline and after
24 weeks by self-report using the EQ-5D
questionnaire [19], which evaluates five domains
of patienthealth/lifestyle (mobility, self-care, usual
activities, pain/discomfort, and anxiety/
depression). Scores in these five domains were
converted to a single utility value (UK VAS set),
with ‘1.00’ indicating ‘full health’ and ‘0.00’
indicating the state ‘deceased’ [16].
Statistical Analysis
Safety and effectiveness outcome measures
were analyzed by age-group (B40 years,
[40–65 years, and [65 years) and by pre-study
insulin experience (insulin-experienced and
insulin-naı¨ve). All variables were analyzed
using the full analysis set (FAS), defined as all
patients with a baseline visit who used insulin
detemir at least once. For hypoglycemia, the
proportion of participants reporting at least one
event was analyzed using McNemar’s test. The
proportion of participants reporting
hypoglycemia at baseline and 24 weeks was
also analyzed according to sulfonylurea use at
the study visits. Changes from baseline in
effectiveness measures were assessed using
Student’s paired t test. Data analysis was
performed by Novo Nordisk using SAS
Version 9.1.3 (SAS Institute Inc., Cary, North
Carolina, USA). All statistical tests were two-
sided, using a pre-specified 5% significance
level.
Table 1 Baseline patient and disease characteristics by age-group
Baseline variable Age £40 years Age >40–65 years Age >65 years
Entire cohort, n 1,467 10,967 2,807
Insulin status, n
Insulin-experienced 258 2,286 840
Insulin-naı¨ve 1,209 8,681 1,967
Gender (male/female) (%)a 63.4/36.6 55.4/44.6 43.4/56.6
Mean (SD) age (years) 34.9 (5.8) 53.0 (6.5) 71.6 (5.0)
Mean (SD) body weight (kg)b 77.4 (16.1) 77.3 (16.7) 69.5 (14.6)
Mean (SD) BMI (kg/m2)c 28.0 (5.2) 28.5 (5.4) 26.9 (5.0)
Mean (SD) age at diagnosis (years)d 30.9 (5.6) 45.0 (7.1) 59.3 (9.0)
Mean (SD) diabetes duration (y)d 4.3 (3.3) 8.0 (5.2) 12.3 (7.8)
Due to the observational nature of this study, not all baseline data were recorded
BMI body mass index
a n = 1,464, n = 10,950, n = 2,805 for the B40,[40–65 and[65 years age-groups, respectively
b n = 1,401, n = 10,454, n = 2,589 for the B40,[40–65 and[65 years age-groups, respectively
c n = 1,323, n = 9,726, n = 2,392 for the B40,[40–65 and[65 years age-groups, respectively
d n = 1,422, n = 10,812, n = 2,763 for the B40,[40–65 and[65 years age-groups, respectively




Baseline characteristics of the participants are
shown in Table 1. A total of 15,241 people with
type 2 diabetes (22.8% of the overall A1chieve
study population) were treated with insulin
detemir (±OGLDs), including 1,467 aged
B40 years, 10,967 aged [40–65 years, and
2,807 aged [65 years. Most study participants
were insulin-naı¨ve before the study.
Safety Measures
Insulin Dose
In all three age-groups, mean total insulin dose
appeared to increase slightly between baseline
(when patients started or switched to insulin
detemir) and 24 weeks (Table 2).
All Hypoglycemia Events
At 24 weeks, the proportion of participants
experiencing hypoglycemia in the entire
cohort and in insulin-experienced patients was
significantly reduced from baseline in all age-
groups (Table 3). In insulin-naı¨ve patients, the
proportion experiencing hypoglycemia was
significantly reduced from baseline in the
B40 years age-group and significantly
increased in the [65 years age-group at
24 weeks (Table 3). There was no significant
change between baseline and 24 weeks in the
proportion of participants experiencing
hypoglycemia in the [40–65 years age-group
(Table 3). At both baseline and week 24, there
was no indication in any age-group that the
proportion experiencing hypoglycemia was
higher in participants taking sulfonylureas
compared with those who were not (Table 3).
Major Hypoglycemia Events
In the entire cohort and in insulin-experienced
patients, the proportion of participants
experiencing major hypoglycemia was
significantly reduced at 24 weeks relative to
baseline (Table 3). In insulin-naı¨ve patients,
the proportion of patients experiencing major
hypoglycemia was significantly reduced from
baseline in the [40–65 and [65 years age-
groups at 24 weeks, and no major
hypoglycemia was reported in the B40 years
age-group at 24 weeks (Table 3).
Nocturnal Hypoglycemia Events
The proportion of participants experiencing
nocturnal hypoglycemia was significantly
lower at 24 weeks versus baseline in all three
Table 2 Insulin dose at baseline (when patients started or switched to insulin detemir) and 24 weeks
Mean (SD) insulin dose (U/kg) Age £40 years Age >40–65 years Age >65 years
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Entire cohort 0.29 (0.16) 0.37 (0.20) 0.26 (0.15) 0.37 (0.20) 0.27 (0.16) 0.38 (0.21)
n 1,401 1,171 10,453 8,755 2,589 2,048
Insulin-experienced 0.35 (0.20) 0.45 (0.27) 0.35 (0.19) 0.45 (0.23) 0.36 (0.19) 0.45 (0.24)
n 244 201 2,163 1,812 766 585
Insulin-naı¨ve 0.28 (0.14) 0.36 (0.18) 0.24 (0.13) 0.35 (0.18) 0.23 (0.13) 0.35 (0.19)
n 1,157 970 8,290 6,943 1,823 1,463
Due to the observational nature of this study not all measures were reported or collected
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age-groups in the entire cohort and in insulin-
experienced patients (Table 3). In insulin-naı¨ve
patients, the proportion experiencing nocturnal
hypoglycemia was significantly reduced from
baseline in the B40 years age-group and
significantly increased in the [65 years age-
group, with no significant change in the
[40–65 years age-group (Table 3).
SADRs
There were seven reports of SADRs in the 15,241
people with type 2 diabetes receiving insulin
detemir (±OGLDs). None of these were in the
B40 years age-group. Six SADRs were reported
in the[40–65 years age-group (three episodes of
hyperglycemia and three episodes of
hypoglycemia). Of these, two episodes of
Table 3 Self-reported hypoglycemia events in the preceding 4 weeks of the study visit at baseline and after 24 weeks of
treatment with insulin detemir
Measurement Proportion of patients with at least one event, % (event/person-year)
Age £40 years Age >40–65 years Age >65 years
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Hypoglycemia (overall)
Entire cohort 6.4 (1.89) 3.3*** (0.91) 7.3 (2.56) 4.7*** (1.42) 10.0 (3.75) 6.6*** (1.88)
n 1,467 1,279 10,967 9,677 2,807 2,334
Insulin-experienced 16.3 (6.40) 6.3*** (2.16) 19.9 (7.98) 6.0*** (1.69) 23.9 (9.67) 8.1*** (2.18)
n 258 223 2,286 1,991 840 680
Insulin-naı¨ve 4.3 (0.92) 2.7* (0.65) 3.9 (1.13) 4.4 (1.35) 4.1 (1.22) 6.0** (1.76)
n 1,209 1,056 8,681 7,686 1,967 1,654
Sulfonylurea 6.2 (1.57) 3.0* (0.87) 6.0 (1.91) 4.9 (1.40) 7.1 (2.69) 7.1 (2.04)
n 942 657 8,261 5,517 1,913 1,199
No sulfonylurea 6.9 (2.45) 3.5 (0.96) 11.2 (4.53) 4.5* (1.44) 16.3 (6.02) 6.2** (1.72)
n 525 622 2,706 4,160 894 1,135
Hypoglycemia (major)a
Entire cohort 0.8 (0.12) 0** (0) 1.1 (0.23) 0.0*** (0.00) 1.6 (0.37) 0.0*** (0.01)
Insulin-experienced 3.5 (0.55) 0** (0) 3.5 (0.85) 0.1*** (0.01) 4.0 (1.02) 0.1*** (0.02)
Insulin-naı¨ve 0.2 (0.03) 0 (0) 0.4 (0.07) 0.0*** (0.00) 0.5 (0.09) 0** (0)
Hypoglycemia (nocturnal)a
Entire cohort 3.1 (0.53) 1.0*** (0.26) 3.5 (0.81) 1.7*** (0.41) 4.5 (1.10) 2.3*** (0.47)
Insulin-experienced 7.4 (1.51) 2.7* (0.93) 11.3 (2.84) 1.7*** (0.42) 12.3 (3.10) 2.4*** (0.44)
Insulin-naı¨ve 2.2 (0.32) 0.7*** (0.12) 1.5 (0.27) 1.7 (0.41) 1.2 (0.25) 2.2* (0.48)
Due to the observational nature of this study not all measures were reported or collected
* p\0.05 for proportion of patients with at least one event at 24 weeks relative to baseline
** p\0.01 for proportion of patients with at least one event at 24 weeks relative to baseline
*** p\0.001 for proportion of patients with at least one event at 24 weeks relative to baseline
a n for each cohort same as for hypoglycemia (overall) data
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hyperglycemia and two episodes of
hypoglycemia were probably related to insulin
detemir treatment (with good reasons and
sufficient documentation to assume a causal
relationship), and one episode of hyperglycemia
and one episode of hypoglycemia were possibly
related (a causal relationship was conceivable
and could not be dismissed). One SADR (an
episode of hypoglycemia) was reported in the
[65 years age-group, which was probably
related to insulin detemir treatment.
Body Weight
In the B40 and [40–65 years age-groups, body
weight was significantly reduced at 24 weeks; in
the [65 years age-group, body weight was
significantly increased (Table 4). In insulin-
experienced patients, significant reduction in
body weight was observed in the [40–65 and
[65 years age-groups, and there was no
significant change in the B40 years age-group
(Table 4). In insulin-naı¨ve patients, significant
reduction in body weight was observed in the
B40 and [40–65 years age-groups, and the




Significant reductions in HbA1c were achieved
in all age-groups and in insulin-experienced and
insulin-naı¨ve patients at 24 weeks (Table 4;
Fig. 1). The percentage of participants with
HbA1c\7.0% appeared to increase between
baseline and 24 weeks in all three age-groups
in insulin-experienced and insulin-naı¨ve
(Table 4). In the [65 years age-group, the
percentage with HbA1c\7.5% was 12.0% at
baseline and 53.8% at 24 weeks. The proportion
of this age-group with HbA1c\7.5% at baseline
appeared to be higher in insulin-experienced
patients (20.0%) compared with insulin-naı¨ve
patients (8.8%). At 24 weeks, the percentage of
the [65 years age-group with HbA1c\7.5%
appeared to be similar in insulin-experienced
(51.5%) and insulin-naı¨ve patients (54.7%).
Significant reductions in FPG were observed
between baseline and 24 weeks for all age-
groups and in both insulin-experienced and
insulin-naı¨ve patients (Table 4). PPG levels were
also significantly lowered in all age-groups at
24 weeks (Table 4). In both insulin-experienced
and insulin-naı¨ve patients, all age-groups
showed significant improvements in FPG and
PPG at 24 weeks (Table 4).
HRQoL
All age-groups, whether insulin-experienced or
insulin-naı¨ve, had significantly improved UK
VAS scores at 24 weeks (Table 4).
DISCUSSION
This sub-analysis of the A1chieve study reports
the results for people with poorly controlled
type 2 diabetes of different age-groups who
switched to, or started, insulin therapy with
insulin detemir. The data showed that 24-week
treatment with insulin detemir (±OGLDs) in
routine clinical practice resulted in improved
glycemic control for all age-groups, in both
insulin-experienced and insulin-naı¨ve patients.
HbA1c levels were significantly reduced in all
age-groups overall and in insulin-experienced
and insulin-naı¨ve patients after 24-week
treatment with insulin detemir. FPG and PPG
levels were significantly improved across all age-
groups and in insulin-naı¨ve or insulin-
experienced patients.
Insulin detemir was well tolerated in all age-
groups. Not surprisingly, baseline hypoglycemia
appeared to be more frequent in insulin-
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experienced patients than insulin-naı¨ve
patients, and in patients aged [65 years than
younger patients. The improvement in the
incidence of hypoglycemia when switching to
insulin detemir is important for all age-groups
but especially for patients aged[65 years, given
the increased risk of severe hypoglycemia [20,
21]. The data for this age-group also show that
major hypoglycemia is significantly reduced at
week 24 compared with baseline. Between
baseline and 24 weeks, the proportion of
patients in the [65 years age-group with
HbA1c\7.0% increased from 5.6% to 29.5%.
While this HbA1c level may not be a target in
the elderly population, better control of
diabetes could have resulted in a higher
frequency of hypoglycemia.
The observed increase in HRQoL in all age-
groups may reflect the overall improvements in
incidence of hypoglycemia reported for insulin
detemir treatment [22, 23]. It is surprising that
overall hypoglycemia and nocturnal
hypoglycemia were significantly reduced at
24 weeks compared with baseline in insulin-
naı¨ve patients in the B40 years age-group, while
there was no change in the [40–65 years age-
group and a significant increase in the[65 years
age-group. There is no clear explanation for the
reduced hypoglycemia in the B40 years age-
group, but it could be related to pre-study
OGLD use; for example, sulfonylureas are
associated with an increased risk of
hypoglycemia [24]. There was a reduction in
sulfonylurea use between baseline and week 24
in this age-group that could potentially have
contributed to a lower rate of hypoglycemia.
However, a similar decrease in sulfonylurea use
was observed in the other age-groups and there
was no evidence for a higher rate of
hypoglycemia in participants taking
sulfonylureas compared with those who were
not. Therefore, an alternative explanation may
be needed.
Interestingly, in patients aged [65 years,
those switching to insulin detemir had
significant weight loss while those starting
insulin detemir had significant weight gain at
24 weeks. The weight changes were significant
but small, and therefore, may not be clinically
important. Furthermore, this difference
between insulin-naı¨ve and insulin-experienced
patients was not observed in the other age-
Fig. 1 Effectiveness results by age-group and pre-study insulin experience
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groups, and in fact weight generally was
reduced at 24 weeks. In other observational
studies in people with type 2 diabetes, 24-week
[13] and 26-week [14] treatment with insulin
detemir led to small significant reductions in
weight.
Observational studies such as A1chieve allow
a large number of outcomes to be assessed in a
large population, and sub-analyses can be
performed to evaluate which patients benefit
from each treatment. Unlike RCTs,
observational studies are not randomized and
are more susceptible to selection bias. However,
the large number of patients assessed in
A1chieve may help to minimize possible
confounding factors. This study did not
include a control group or control for
concomitant medication or dietary intake,
which is difficult to measure, and some
outcomes relied on self-reported information,
participant recall, or diverse diaries. A
limitation with the hypoglycemia data is that
they were based on patient recall of
hypoglycemia in the 4 weeks preceding the
study visits, which could have led to an
underestimation of mild hypoglycemia events.
The incidence of hypoglycemia, especially mild
events, could also be underestimated in non-
Western countries where blood glucose may not
be measured very frequently. However, the
advantage of this study is the real-world
clinical setting, including actual practice
patterns and a broader population than a RCT.
Despite the limitation that reporting of
hypoglycemia relied on patient recall, the
significant improvement in glycemic control
(with HbA1c reduced by 1.4–2.4%), with a
modest proportion of patients experiencing
hypoglycemia, is of clinical relevance. In
general, RCTs have either a participant age
limit or exclude elderly people with diabetes
who have certain complications. Hence, it is
noteworthy that data from even the smallest
sub-group of this large observational study will
help to elucidate the safety and effectiveness of
insulin detemir in different age-groups.
Consistent with the results of other studies
[13, 14] and the overall A1chieve population
[15], the results of this sub-analysis suggest that
insulin detemir is well tolerated, and improves
glycemic control and HRQoL in most groups of
people with poorly controlled type 2 diabetes
versus their previous insulin regimen.
Improvements in glycemic control and HRQoL
were observed across a wide range of age-
groups, and both in patients initiating insulin
therapy with insulin detemir and those
switching from other insulin regimens. The
proportion of participants reporting
hypoglycemia events was reduced in all age-
groups in the entire cohort and in insulin-
experienced patients, and the reduced
proportion of elderly people with type 2
diabetes reporting major hypoglycemia is
particularly important.
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